Literature DB >> 11581330

Frontiers of hypoxia research: acute mountain sickness.

R C Roach1, P H Hackett.   

Abstract

Traditionally, scientists and clinicians have explored peripheral physiological responses to acute hypoxia to explain the pathophysiological processes that lead to acute mountain sickness (AMS) and high-altitude cerebral edema (HACE). After more than 100 years of investigation, little is yet known about the fundamental causes of the headache and nausea that are the main symptoms of AMS. Thus, we review the evidence supporting a change in focus to the role of the central nervous system in AMS. Our justification is (i) that the symptoms of AMS and HACE are largely neurological, (ii) that HACE is considered to be the end-stage of severe AMS and was recently identified as a vasogenic edema, opening the door for a role for blood-brain barrier permeability in AMS, (iii) that new, non-invasive techniques make measurement of brain water levels and cerebral blood volume possible and (iv) that the available experimental evidence and theoretical arguments support a significant role for brain swelling in the pathophysiology of AMS. We believe that an examination of the responses of the central nervous system to acute hypoxia will reveal important new pathophysiological processes that may help explain AMS and HACE.

Entities:  

Mesh:

Year:  2001        PMID: 11581330     DOI: 10.1242/jeb.204.18.3161

Source DB:  PubMed          Journal:  J Exp Biol        ISSN: 0022-0949            Impact factor:   3.312


  54 in total

1.  Cholinesterase inhibitors ameliorate spatial learning deficits in rats following hypobaric hypoxia.

Authors:  Sangu Muthuraju; Panchanan Maiti; Preeti Solanki; Alpesh Kumar Sharma; Shashi Bala Singh; Dipti Prasad; Govindasamy Ilavazhagan
Journal:  Exp Brain Res       Date:  2010-05-11       Impact factor: 1.972

2.  Prevention and Treatment of High-altitude Illness in Travelers.

Authors:  David R. Murdoch
Journal:  Curr Infect Dis Rep       Date:  2004-02       Impact factor: 3.725

Review 3.  High altitude hypoxia: an intricate interplay of oxygen responsive macroevents and micromolecules.

Authors:  S Sarkar; P K Banerjee; W Selvamurthy
Journal:  Mol Cell Biochem       Date:  2003-11       Impact factor: 3.396

Review 4.  Neuropsychological functioning associated with high-altitude exposure.

Authors:  Javier Virués-Ortega; Gualberto Buela-Casal; Eduardo Garrido; Bernardino Alcázar
Journal:  Neuropsychol Rev       Date:  2004-12       Impact factor: 7.444

5.  The protective role of 5-hydroxymethyl-2-furfural (5-HMF) against acute hypobaric hypoxia.

Authors:  Ming-Ming Li; Li-Ying Wu; Tong Zhao; Kui-Wu Wu; Lei Xiong; Ling-Ling Zhu; Ming Fan
Journal:  Cell Stress Chaperones       Date:  2011-04-15       Impact factor: 3.667

6.  Distortion product otoacoustic emissions for assessment of intracranial hypertension at extreme altitude?

Authors:  Bernhard Olzowy; Gregor von Gleichenstein; Martin Canis; Klaus Mees
Journal:  Eur J Appl Physiol       Date:  2008-01-11       Impact factor: 3.078

7.  The role of pulse oximetry in chiropractic practice: a rationale for its use.

Authors:  Michael W Hall; Anne M Jensen
Journal:  J Chiropr Med       Date:  2012-06

8.  Overactivation of corticotropin-releasing factor receptor type 1 and aquaporin-4 by hypoxia induces cerebral edema.

Authors:  Shao-Jun Chen; Jia-Fang Yang; Fan-Ping Kong; Ji-Long Ren; Ke Hao; Min Li; Yuan Yuan; Xin-Can Chen; Ri-Sheng Yu; Jun-Fa Li; Gareth Leng; Xue-Qun Chen; Ji-Zeng Du
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-21       Impact factor: 11.205

9.  Bioavailability, tissue distribution, and excretion characteristics of the novel carbonic anhydrase inhibitor tolsultazolamide in rats.

Authors:  Jin-da Wang; Yong-ping Shi; Jing Yin; Zhi-yuan Pan; Wen-yu Cui; Yan-fang Zhang; Hai Wang
Journal:  Acta Pharmacol Sin       Date:  2013-12-16       Impact factor: 6.150

10.  Ophthalmodynamometry for ICP prediction and pilot test on Mt. Everest.

Authors:  Henry W Querfurth; Philip Lieberman; Steve Arms; Steve Mundell; Michael Bennett; Craig van Horne
Journal:  BMC Neurol       Date:  2010-11-01       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.